Patents by Inventor Naohito Ohashi

Naohito Ohashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7329665
    Abstract: An optically active form of the quinazolinone derivatives represented by the general formula (1): [wherein Y represents a phenyl group or C2-C7 alkyl group; E represents —CH? or nitrogen atom; and R represents a C1-C4 alkyl group and so on], or pharmaceutically acceptable salts thereof, has a selective antagonism for the M3 muscarinic receptor and depressant action on the frequency of rhythmic bladder contractions, and it is useful for the treatment of pollakiuria and urinary incontinence.
    Type: Grant
    Filed: August 2, 2002
    Date of Patent: February 12, 2008
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Masami Muraoka, Kazuki Matsui, Takaaki Yamamoto, Koji Morishita, Masatoshi Yuri, Seiji Katayama, Naohito Ohashi
  • Patent number: 7199147
    Abstract: A compound represented by the formula (1): wherein R1—X— indicates that 1 to 4 R1—X— groups are present which may be the same or different, the ring A is a saturated or unsaturated 5-membered heterocyclic ring, X is a single bond, a group represented by the formula: —N(R3)—, —O— or —S—, or the like. R1 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, R2 is a hydrogen atom, a halogen atom, a nitro group, a carboxyl group, a substituted or unsubstituted alkyl group, or the like, and R3 is a hydrogen atom, a substituted or unsubstituted alkyl group, or the like; a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is a useful compound as a therapeutic agent for diseases for which Rho kinase is responsible.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: April 3, 2007
    Assignee: Dainippon Sumitomo Pharma Co., Ltd.
    Inventors: Naonori Imazaki, Masafumi Kitano, Naohito Ohashi, Kazuki Matsui
  • Publication number: 20050032819
    Abstract: An optically active form of the quinazolinone derivatives represented by the general formula (1): [wherein Y represents a phenyl group or C2-C7 alkyl group; E represents —CH? or nitrogen atom; and R represents a C1-C4 alkyl group and so on], or pharmaceutically acceptable salts thereof, has a selective antagonism for the M3 muscarinic receptor and depressant action on the frequency of rhythmic bladder contractions, and it is useful for the treatment of pollakiuria and urinary incontinence.
    Type: Application
    Filed: August 2, 2002
    Publication date: February 10, 2005
    Inventors: Masami Muraoka, Kazuki Matsui, Takaaki Yamamoto, Koji Morishita, Masatoshi Yuri, Seiji Katayama, Naohito Ohashi
  • Publication number: 20040138286
    Abstract: A compound represented by the formula (1): 1
    Type: Application
    Filed: December 12, 2003
    Publication date: July 15, 2004
    Inventors: Naonori Imazaki, Masafumi Kitano, Naohito Ohashi, Kazuki Matsui
  • Patent number: 6734205
    Abstract: A compound represented by the following formula: wherein R is a substituted or unsubstituted benzene ring, a fused polycyclic hydrocarbon ring which is substituted or unsubstituted, a monocyclic heterocyclic ring which is substituted or unsubstituted, a polycyclic heterocyclic ring which is substituted or unsubstituted, A and E are independently a single bond, a lower alkylene group or the like, G is a single bond, an oxygen atom or the like, and Y is a —SO3H group or the like, a prodrug of said compound, or a pharmaceutically acceptable salt of said compound or prodrug is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton exchange transport system.
    Type: Grant
    Filed: June 17, 2002
    Date of Patent: May 11, 2004
    Assignee: Sumitomo Pharmaceuticals Company Limited
    Inventors: Masahumi Kitano, Masatoshi Yuri, Naohito Ohashi
  • Patent number: 6645971
    Abstract: A compound given by general formula (1): [wherein T represents oxygen or sulfur atom, Y represents alkyl, cycloalkyl group, etc., ring W represents benzene ring, etc., R1 and R2 represent independently hydrogen atom, lower alkyl group, etc., and R3 represents hydrogen atom, alkyl group, etc. Z represents a group given by formula: {wherein A1 and A2 represent independently hydrogen atom, alkyl group, etc. and G represents straight chain alkylene having 1-6 of the carbon number, etc.} or a group given by formula: {wherein n represents 0, 1 or 2, ring E represents 4-8 membered saturated heterocyclic ring containing nitrogen atom(s), and A3 represents hydrogen atom, alkyl group, etc.}], its prodrug or pharmaceutically acceptable salt thereof is an antagonist against muscarinic receptor that is useful as anticholinergic medicaments, and therefore it is useful as pollakiuria or urinary incontinence remedy.
    Type: Grant
    Filed: April 10, 2001
    Date of Patent: November 11, 2003
    Assignee: Sumitomo Pharmaceuticals Company Limited
    Inventors: Masami Muraoka, Kazuki Matsui, Koji Morishita, Naohito Ohashi
  • Publication number: 20030105118
    Abstract: A compound of the formula (1): 1
    Type: Application
    Filed: October 18, 2002
    Publication date: June 5, 2003
    Inventors: Shuji Masumoto, Masahumi Kitano, Naohito Ohashi
  • Publication number: 20030018056
    Abstract: A compound represented by the following formula: 1
    Type: Application
    Filed: June 17, 2002
    Publication date: January 23, 2003
    Inventors: Masahumi Kitano, Masatoshi Yuri, Naohito Ohashi
  • Patent number: 6452008
    Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety. wherein R1 is hydrogen, alkyl, substituted alkyl, etc.; Y1 is hydrogen, alky, substituted alky, etc.; Y2 and Y3 are indenpently hydrogen, halogen, etc.; and L is alkyl, substituted alkyl, etc.
    Type: Grant
    Filed: May 14, 2001
    Date of Patent: September 17, 2002
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi
  • Patent number: 6420381
    Abstract: A compound of the formula (I): wherein Ring A is substituted or unsubstituted pyridine ring, Y is substituted or unsubstituted alkyl, etc., R1 is hydrogen, or substituted or unsubstituted alkyl, etc., R2 is hydrogen or lower alkyl, R3 is lower alkyl, Z is 1) —D1—Q [D1 is direct bond or divalent C1-8 hydrocarbon, etc., Q is hydroxy, carboxyl, etc.], or 2) —D2M—E—W [D2 is direct bond or divalent C1-8 hydrocarbon, etc., M is oxygen, sulfur, etc., E is direct bond or divalent C1-8 hydrocarbon, etc., W is hydroxyl, carboxyl, etc.], or a prodrug thereof, or a pharmaceutically acceptable salt of the same, which exhibits acyl-CoA: cholesterol acyl transferase (ACAT) inhibitory activity, and is useful as an agent for treatment of hyperlipidemia and atherosclerosis.
    Type: Grant
    Filed: February 9, 2001
    Date of Patent: July 16, 2002
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Masami Muraoka, Hitoshi Ban, Naohito Ohashi
  • Patent number: 6369110
    Abstract: A compound represented by the general formula (1): wherein each of R1, R2, R3, R4 and R5 is a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, an aromatic group, an acyl group or the like; each of Y1, Y2, Y3 and Y4 is a single bond, —CH2—, —O—, —CO— or the like, provided that at least two of Y1 through Y4 are independently a group other than a single bond; and Z may be absent, or one or more Zs may be present and are independently an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a cycloalkenyl group, a saturated heterocyclic group, a halogen atom, a carboxyl group, an alkoxycarbonyl group, an aromatic group, an acyl group or the like, is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton exchange transport system.
    Type: Grant
    Filed: November 27, 2000
    Date of Patent: April 9, 2002
    Assignee: Sumitomo Pharmaceuticals Company
    Inventors: Masahumi Kitano, Naohito Ohashi
  • Publication number: 20010051732
    Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety.
    Type: Application
    Filed: May 14, 2001
    Publication date: December 13, 2001
    Applicant: SUMITOMO PHARMACEUTICALS COMPANY, LIMITED
    Inventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi
  • Patent number: 6300500
    Abstract: A process for preparing a pyridone derivative (4), which comprises reacting the compound (1) with a hypochlorite or a hypobromite or with lead tetraacetate to give the compound (2), and reacting the compound (2) with the compound (3). Said process is preferably especially from the standpoint of safety. wherein R1 is hydrogen, alkyl, substituted alkyl, etc.; Y1 is hydrogen, alky, substituted alky, etc.; Y2 and Y3 are indenpently hydrogen, halogen, etc.; and L is alkyl, substituted alky, etc.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: October 9, 2001
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Masami Muraoka, Koji Morishita, Nagisa Aida, Masashi Tanaka, Masatoshi Yuri, Naohito Ohashi
  • Patent number: 6271251
    Abstract: A substituted guanidine derivative represented by the general formula: or a pharmaceutically acceptable acid addition salt thereof, is useful as a therapeutic or prophylactic agent for diseases caused by the acceleration of the sodium/proton (Na+/H+) exchange transport system, for example, hyperpiesia, arrhythmia, angina pectoris, hypercardia, diabetes, organopathies due to ischemia or ischemia re-perfusion, troubles due to cerebral ischemia, diseases caused by cell over-proliferations, and diseases caused by trouble with endothelial cells.
    Type: Grant
    Filed: June 29, 1999
    Date of Patent: August 7, 2001
    Assignee: Sumitomo Pharmaceuticals Company Limited
    Inventors: Masahumi Kitano, Naohito Ohashi
  • Patent number: 6248772
    Abstract: Novel indoloylguanidine derivatives shown by formula (1), wherein R1 represents one or more, the same or different substituent(s) which is selected from the group consisting of a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a halogen atom, nitro group, an acyl group, carboxyl group, an alkoxycarbonyl group, an aromatic group, and a group shown by formula: —OR3, —NR6R7, —SO2NR6R7 or —S(O)nR40; and R2 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, hydroxy group, an alkoxy group or a group shown by formula: —CH2R20; and which inhibit the Na+/H+ exchanger activity and are useful for the treatment and prevention of a disease caused by increased Na+/H+ exchanger activity, such as hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, disorders associated with ischemia or ischemic reperfusion, cerebro-ischemic disorders; or diseases caus
    Type: Grant
    Filed: June 27, 2000
    Date of Patent: June 19, 2001
    Assignee: Sumitomo Pharmaceuticals Co., Ltd.
    Inventors: Masahumi Kitano, Kazuhiro Nakano, Hideki Yagi, Naohito Ohashi, Atsuyuki Kojima, Tsuyoshi Noguchi, Akira Miyagishi
  • Patent number: 6169107
    Abstract: Novel indoloylguanidine derivatives shown by formula (1), wherein R1 represents one or more, the same or different substituent(s) which is selected from the group consisting of a hydrogen atom, an alkyl group, a substituted alkyl group, an alkenyl group, an alkynyl group, a cycloalkyl group, a halogen atom, nitro group, an acyl group, carboxyl group, an alkoxycarbonyl group, an aromatic group, and a group shown by formula: —OR3, —NR6R7, —SO2NR6R7 or —S(O)nR40; and R2 represents a hydrogen atom, an alkyl group, a substituted alkyl group, a cycloalkyl group, hydroxy group, an alkoxy group or a group shown by formula: —CH2R20; and which inhibit the Na+/H+ exchanger activity and are useful for the treatment and prevention of a disease caused by increased Na+/H+ exchanger activity, such as hypertension, arrhythmia, angina pectoris, cardiac hypertrophy, diabetes, disorders associated with ischemia or ischemic reperfusion, cerebro-ischemic disorders; or diseases caus
    Type: Grant
    Filed: October 17, 1995
    Date of Patent: January 2, 2001
    Assignee: Sumitomo Pharmaceutical Co., Ltd.
    Inventors: Masahumi Kitano, Kazuhiro Nakano, Hideki Yagi, Naohito Ohashi, Atsuyuki Kojima, Tsuyoshi Noguchi, Akira Miyagishi
  • Patent number: 6159974
    Abstract: LDL receptor gene expression promoters containing a 1,2,4-triazine derivative of the formula (I): ##STR1## wherein R.sup.1 is optionally substituted phenyl or heterocycle; R.sup.2 is optionally substituted phenyl, naphthyl, aralkyl, 5- or 6-membered aromatic heterocycle, alkyl, or alkenyl; X is O, S or NR.sup.4 ; R.sup.3 is optionally substituted phenyl, naphthyl, aralkyl, 5- to 6-membered aromatic heterocycle, alkyl, cycloalkyl or alkenyl, provided that when X is NR.sup.4, then it may form an optionally substituted nitrogen-containing heterocycle, or a pharmaceutically acceptable salt thereof, which can increase the expression dose (the amount of mRNA) of LDL receptor gene, and thus increase the amount of LDL receptor, and reduce the serum cholesterol level, and are useful in the treatment of hyperlipidemia.
    Type: Grant
    Filed: September 24, 1999
    Date of Patent: December 12, 2000
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Yoshihide Ueno, Koji Morishita, Masami Muraoka, Naohito Ohashi
  • Patent number: 5977100
    Abstract: A substituted guanidine derivative represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a halogen atom or the like; Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, Y.sub.5, Y.sub.6 and Y.sub.7, which may be the same or different, are independently a single bond, --CH.sub.2 --, --O--, --CO-- or the like, adjacent members of a group consisting of Y.sub.1 through Y.sub.7 being able to be taken together to represent --CH.dbd.CH--, and at least two of Y.sub.1 through Y.sub.7 being independently a group other than a single bond; Z may be absent, or one or more Zs may be present and are, the same or different, independently a substituent for a hydrogen atom bonded to any of the carbon atoms constituting the ring formed by Y.sub.1 through Y.sub.
    Type: Grant
    Filed: May 8, 1998
    Date of Patent: November 2, 1999
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Masahumi Kitano, Naohito Ohashi
  • Patent number: 5843957
    Abstract: Naphthyridine derivative of the formula: ##STR1## wherein Ring A is substituted or unsubstituted pyridine, X is --N(R.sup.2)--CO--(R.sup.2 is H, alkyl, substituted alkyl, etc.), Z is a direct bond, --NH--, C.sub.1 -C.sub.2 alkylene, or --CH.dbd.CH--, Y is alkyl, substituted alkyl, aromatic group or substituted aromatic group, etc., B is alkyl, substituted alkyl, aromatic group or substituted aromatic group, or an acid addition salt thereof, these compounds having acyl-CoA: cholesterol acyl transferase inhibitory activity, and being useful as an agent for prophylaxis or treatment of hyperlipidemia, atherosclerosis, and related diseases thereof.
    Type: Grant
    Filed: November 25, 1997
    Date of Patent: December 1, 1998
    Assignee: Sumitomo Pharmaceuticals Company, Ltd.
    Inventors: Masami Muraoka, Katsuhisa Ioriya, Naohito Ohashi, Hideki Yagi
  • Patent number: 5834454
    Abstract: A substituted guanidine derivative represented by the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are independently a hydrogen atom, an unsubstituted alkyl group, a substituted alkyl group, a halogen atom or the like; Y.sub.1, Y.sub.2, Y.sub.3, Y.sub.4, Y.sub.5, Y .sub.6 and Y.sub.7, which may be the same or different, are independently a single bond, --CH.sub.2 --, --O--, --CO--or the like, adjacent members of a group consisting of Y.sub.1 through Y.sub.7 being able to be taken together to represent --CH.dbd.CH--, and at least two of Y.sub.1 through Y.sub.7 being independently a group other than a single bond; Z may be absent, or one or more Zs may be present and are, the same or different, independently a substituent for a hydrogen atom bonded to any of the carbon atoms constituting the ring formed by Y.sub.1 through Y.sub.
    Type: Grant
    Filed: January 28, 1997
    Date of Patent: November 10, 1998
    Assignee: Sumitomo Pharmaceuticals Company, Limited
    Inventors: Masahumi Kitano, Naohito Ohashi